设为首页 加入收藏

TOP

Sodium Citrate and Citric Acid Oral Solution USP
2015-05-24 21:45:35 来源: 作者: 【 】 浏览:688次 评论:0
  • SPL UNCLASSIFIED SECTION

     

    A Sugar-Free Systemic Alkalizer

  • DESCRIPTION

     

    Sodium Citrate and Citric Acid Oral Solution USP is a stable and pleasant-tasting systemic alkalizer containing sodium citrate and citric acid in a sugar-free base. It is a nonparticulate neutralizing buffer.

    Sodium Citrate and Citric Acid Oral Solution USP contains in each teaspoonful (5 mL):

    SODIUM CITRATE Dihydrate 500 mg (0.34 Molar)
    CITRIC ACID Monohydrate 334 mg (0.32 Molar)

    Each mL contains 1 mEq sodium ion and is equivalent to 1 mEq bicarbonate (HCO3).

    INACTIVE INGREDIENTS: Flavoring, polyethylene glycol, propylene glycol, purified water, sodium benzoate, and sorbitol solution.

  • CLINICAL PHARMACOLOGY

     

    Sodium citrate is absorbed and metabolized to sodium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of sodium citrate is excreted in the urine unchanged.

  • INDICATIONS AND USAGE

     

    Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.

    Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods.

  • CONTRAINDICATIONS

     

    Patients on sodium-restricted diets or with severe renal impairment.

  • PRECAUTIONS

     

    Sodium Citrate and Citric Acid Oral Solution USP should be used with caution by patients with low urinary output unless under the supervision of a physician. This product should not be administered concurrently with aluminum-based antacids. Patients should be directed to dilute adequately with water and preferably, to take each dose after meals to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema, and toxemia of pregnancy. Periodic examinations and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.

  • ADVERSE REACTIONS

     

    Sodium Citrate and Citric Acid Oral Solution USP is generally well tolerated, without any unpleasant side effects, when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of alkalosis, especially in the presence of hypocalcemia.

  • OVERDOSAGE

     

    Overdosage with sodium salts may cause diarrhea, nausea and vomiting, hypernoia, and convulsions.

  • DOSAGE AND ADMINISTRATION

     

    Sodium Citrate and Citric Acid Oral Solution USP should be taken diluted in water, followed by additional water, if desired. SHAKE WELL BEFORE USING.

  • For Systemic Alkalization

     

     

    Usual Adult Dose

    2 to 6 teaspoonfuls (10 to 30 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician.

     

    Usual Pediatric Dose

    1 to 3 teaspoonfuls (5 to 15 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician. For children under two years of age, use is based on consultation with a physician.

  • As a neutralizing buffer

     

    3 teaspoonfuls (15 mL), diluted with 15 mL water, taken as a single dose, or as directed by a physician.

  • HOW SUPPLIED

     

    Sodium Citrate and Citric Acid Oral Solution USP (colorless, grape flavor) is supplied in the following oral dosage forms: NDC 0121-0595-16 (16 fl oz bottles), NDC 0121-0595-15 (Unit dose cups of 15 mL, 10 × 10's) and NDC 0121-0595-30 (Unit dose cups of 30 mL, 10 × 10's).

     

    STORAGE

    Keep tightly closed. Store at controlled room temperature, 20° -25° C (68° -77° F). Protect from freezing.

  • SPL UNCLASSIFIED SECTION

     

    Rx ONLY

    Manufactured By:
    Pharmaceutical Associates, Inc.
    Greenville, SC 29605

    NDC 0121-0595

    05950199      R01/99

  • PRINCIPAL DISPLAY PANEL

     

    Sodium Citrate and Citric Acid Oral Solution USP

    3 g/2g per 30 mL

    Sugar Free

    5 Cups

    bag label
  • INGREDIENTS AND APPEARANCE
    SODIUM CITRATE AND CITRIC ACID  sodium citrate and citric acid monohydrate solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55154-9410(NDC:0121-0595)
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    SODIUM CITRATE (UNII: 1Q73Q2JULR) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) SODIUM CITRATE 500 mg  in 5 mL
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) ANHYDROUS CITRIC ACID 334 mg  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    WATER (UNII: 059QF0KO0R)  
    SODIUM BENZOATE (UNII: OJ245FE5EU)  
    SORBITOL (UNII: 506T60A25R)  
    Product Characteristics
    Color      Score     
    Shape   Size  
    Flavor GRAPE Imprint Code  
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:55154-9410-5 5 in 1 BAG    
    1   30 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product    
     
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    Unapproved drug other   01/01/1969  
    Labeler - Cardinal Health (188557102)
    Establishment
    Name Address ID/FEI Business Operations
    Cardinal Health   188557102 REPACK(55154-9410) 
  • 以下是“全球医药”详细资料
    Tags: 责任编辑:admin
    】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
    分享到QQ空间
    分享到: 
    上一篇Sodium Citrate and Citric Acid .. 下一篇Sodium Citrateand Citric Acid O..

    相关栏目

    最新文章

    图片主题

    热门文章

    推荐文章

    相关文章

    广告位